Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss
It is suggested that while semaglutide is effective for weight loss, it is not economically viable over the long term compared with ESG, which remains a cost-saving alternative for this patient population.
Abstract
Key Points Question What is the cost-effectiveness viability of semaglutide compared with endoscopic sleeve gastroplasty (ESG) over 5 years for individuals with class II obesity? Findings In this economic evaluation study using a Markov cohort model analysis, ESG was found to be a cost-effective strategy, offering greater weight loss and cost savings. The annual cost of semaglutide would need to be reduced 3-fold, from $13 618 to $3591, for it to be a cost-competitive alternative. Meaning The study suggests that while semaglutide is effective for weight loss, it is not economically viable over the long term compared with ESG, which remains a cost-saving alternative for this patient population.